American Journal of Medical Genetics

Cover image for American Journal of Medical Genetics

Special Issue: X-Linked Mental Retardation 2

January - February 1986

Volume 23, Issue 1-2

Pages fmi–fmi, 1–737

Currently known as: American Journal of Medical Genetics Part A

  1. Masthead

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. You have free access to this content
      Masthead (page fmi)

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230101

  2. Editorial Comment

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. On the gates of hell and a most unusual gene (pages 1–10)

      John M. Opitz and James F. Renolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230102

  3. Conference Report

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Second international workshop on the fragile X and on X-linked mental retardation (pages 11–67)

      Gillian Turner, John M. Opitz, W. Ted Brown, Kay E. Davies, Patricia A. Jacobs, Edmund C. Jenkins, Margareta Mikkelsen, Michael W. Partington, Grant R. Sutherland and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230103

  4. Articles

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Bibliography on X-linked mental retardation and related subjects III (1986) (pages 69–99)

      John M. Opitz, Mary C. Holt, Lavelle M. Spano and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230104

  5. Invited Editorial Comment

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. X-linked mental retardation: Caveats in genetic counselling (pages 101–109)

      M. W. Partington, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230105

  6. Articles

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Female relatives in families with the fragile X syndrome (pages 111–126)

      M. W. Partington, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230106

  7. I. Clinical Aspects: A. Phenotype

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. X-linked intellectual handicap and precocious puberty with obesity in carrier females (pages 127–137)

      Athel Hockey, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230107

  8. Addendum

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. You have free access to this content
      Addendum (page 137)

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230108

  9. I. Clinical Aspects: A. Phenotype

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Cognitive profiles and the spectrum of clinical manifestations in heterozygous fra(X) females (pages 139–156)

      Melinda B. Kemper, Randi J. Hagerman, Razia S. Ahmad, Robin Mariner, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230109

    2. The female and the Fragile X. A study of 144 obligate female carriers (pages 157–169)

      Jean-Pierre Fryns, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230110

    3. Dermatoglyphic indices of males with the fragile X syndrome and of the female heterozygotes (pages 171–178)

      Nancy E. Simpson, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230111

    4. Oral findings in fragile X syndrome (pages 179–187)

      W. Craig Shellhart, Dr. Paul S. Casamassimo, Randi J. Hagerman, Gary K. Belanger, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230112

    5. Aortic root dilatation and mitral valve prolapse in the fragile X syndrome (pages 189–194)

      James P. Loehr, David P. Synhorst, Robert R. Wolfe, Dr. Randi J. Hagerman, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230113

    6. Speech disturbances (cluttering) in mildly impaired males with the Martin-Bell/fragile X syndrome (pages 195–206)

      Donna M. Hanson, Alfred W. Jackson III, Randi J. Hagerman M.D., John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230114

  10. Brief Clinical Report

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Metaphyseal dysostosis and congenital nystagmus in a male infant with the fragile X syndrome (pages 207–211)

      Dr. Charles A. Williams, Eduardo S. Cantú, Jaime L. Frías, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230115

  11. I. Clinical Aspects: A. Phenotype

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Partial fra(X) phenotype with megalotestes in fra(X)-negative patients with acquired lesions of the central nervous system (pages 213–219)

      Jean-Pierre Fryns, Annemie Dereymaeker, Margot Hoefnagels, Philip Volcke, Herman Van den Berghe, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230116

    2. Cerebral gigantism (Sotos syndrome) in two patients with fra(X) chromosomes (pages 221–226)

      Frits A. Beemer, Henk Veenema, Johanna M. de Peter, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230117

    3. Gonadal function in men with the Martin-Bell (fragile-X) syndrome (pages 227–239)

      Gary D. Berkovitz, Don P. Wilson, Nancy J. Carpenter, Terry R. Brown, Claude J. Migeon, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230118

  12. I. Clinical Aspects: B. Folic Acid Treatment

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome (pages 241–262)

      Randi J. Hagerman M.D., Alfred W. Jackson, Andrew Levitas, Marcia Braden, Pamela McBogg, Melinda Kemper, Loris McGavran, Rebecca Berry, Irwin Matus, Paul J. Hagerman, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230119

    2. High dose folic acid treatment of fragile (X) males (pages 263–271)

      W. Ted Brown, Ira L. Cohen, Gene S. Fisch, Enid G. Wolf-Schein, Valerie A. Jenkins, Mazhar N. Malik, Edmund C. Jenkins, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230120

    3. Folic acid treatment in males and females with fragile-(X)-syndrome (pages 273–289)

      Dr. U. Froster-Iskenius, K. Bödeker, T. Oepen, R. Matthes, U. Piper, E. Schwinger, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230121

    4. Assessment of behavior change in a fragile-X syndrome male treated with folic acid (pages 291–296)

      Thomas E. Wells, Lynda S. Madison, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230122

  13. I. Clinical Aspects: C. Prenatal Diagnosis

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. The prenatal detection of the fragile X chromosome: Review of recent experience (pages 297–311)

      Edmund C. Jenkins, W. Ted Brown, Miriam G. Wilson, Ming S. Lin, Omar S. Alfi, E. Robert Wassman, Judith Brooks, Charlotte J. Duncan, Annette Masia, Michael S. Krawczun, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230123

    2. Second trimester prenatal diagnosis of the fragile X (pages 313–324)

      Niels Tommerup, Pertti Aula, Björn Gustavii, Arvid Heiberg, Gösta Holmgren, Harriet von Koskull, Jaakko Leisti, Margareta Mikkelsen, Felix Mitelman, Karen B. Nielsen, Peter Steinbach, Sabine Stengel-Rutkowski, Jan Wahlström, Klaus Zang, Merve Zankl, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230124

    3. Prenatal diagnosis of the fra(X) syndrome (pages 325–340)

      Lawrence R. Shapiro, Patrick L. Wilmot, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230125

    4. Fragile X and autism: A multicenter survey (pages 341–352)

      W. Ted Brown, Edmund C. Jenkins, Ira L. Cohen, Gene S. Fisch, Enid G. Wolf-Schein, Anne Gross, Lynn Waterhouse, Debra Fein, Ann Mason-Brothers, Edward Ritvo, Bertram A. Ruttenberg, William Bentley, Salvador Castells, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230126

    5. Infantile autism: An occasional manifestation of fragile (X) mental retardation (pages 353–358)

      Barbara C. McGillivray, Diana S. Herbst, Frederick J. Dill, H. Joyce Sandercock, Bluma Tischler, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230127

    6. An analysis of autism in fifty males with the fragile X syndrome (pages 359–374)

      Dr. Randi J. Hagerman, Alfred W. Jackson III, Andrew Levitas, Bernard Rimland, Marcia Braden, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230128

    7. Autism in fragile X females (pages 375–380)

      Dr. Randi J. Hagerman, Albert E. Chudley, Joan H. Knoll, Alfred W. Jackson III, Melinda Kemper, Razia Ahmad, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230129

    8. Fra(2) (q13) and inv(9) (pllq12) in autism: Causal relationship? (pages 381–392)

      Parul Jayakar, Albert E. Chudley, Mano Ray, Jane A. Evans, Jack Perlov, Rox Wand, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230130

    9. Psychiatric disability associated with the fragile X chromosome (pages 393–401)

      A. L. Reiss, C. Feinstein, K. E. Toomey B. Goldsmith, K. Rosenbaum, M. A. Caruso, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230131

    10. Infantile autism and the fragile X. A swedish multicenter study (pages 403–408)

      Jan Wahlström, Christopher Gillberg, Karl-Henrik Gustavson, Gösta Holmgren, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230132

  14. II. Cytogenetic Aspects: A. Fragile Site Expression

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Effects of nucleotides on expression of the folate sensitive fragile sites (pages 409–417)

      Dr. Grant R. Sutherland, Elizabeth Baker, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230133

    2. Clinical implications and classification of the constitutive fragile sites (pages 419–427)

      Dr. Art Daniel, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230134

    3. Somatic cell hybrid studies of fragile (X) expression in a carrier female and transmitting male (pages 429–443)

      David H. Ledbetter, Susan D. Airhart, Robert L. Nussbaum, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230135

    4. Caffeine enhances fragile (X) expression in somatic cell hybrids (pages 445–455)

      David H. Ledbetter, Susan D. Airhart, Robert L. Nussbaum, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230136

    5. A rodent-human hybrid containing Xq24-qter translocated to a hamster chromosome expresses the Xq27 folate-sensitive fragile site (pages 457–466)

      Robert L. Nussbaum, Susan D. Airhart, David H. Ledbetter, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230137

    6. Fragile X expression increased by low cell-culture density (pages 467–473)

      Michael S. Krawczun, Kusum P. Lele, Edmund C. Jenkins, W. Ted Brown, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230138

    7. Fragile X chromosome frequency is consistent temporally and within replicate cultures (pages 475–481)

      Edmund C. Jenkins, Bruce R. Kastin, Michael S. Krawczun, Kusum P. Lele, Wayne P. Silverman, W. Ted Brown, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230139

    8. Variability of thymidylate synthase activity in whole blood cultures treated with FUdR (pages 483–490)

      Susan L. Sklower, Edmund C. Jenkins, Melba L. Anderson, Colin B. Chan, W. Ted Brown, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230140

    9. Mouse chromosome fragility (pages 491–509)

      Dr. Maureen M. Sanz, Edmund C. Jenkins, W. Ted Brown, Muriel T. Davisson, Monica J. Kevin, Thomas H. Roderick, Wayne P. Silverman, Henryk M. Wisniewski, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230141

  15. Letter to the Editor

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Methionine metabolism and fragile X expression (pages 511–514)

      Patricia N. Howard-Peebles, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230142

  16. II. Cytogenetic Aspects: B. Cytogenetics

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Fragile X: Carrier detection in pregnancy (pages 527–530)

      Niels Tommerup, Gösta Holmgren, Peter Steinbach, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230144

    2. Frequency of tri- or multiradial configurations in fragile X identification (pages 531–535)

      Edmund C. Jenkins, Charlotte J. Duncan, Michael S. Krawczun, Lisa M. Berns, Maureen M. Sanz, W. Ted Brown, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230145

    3. Sex chromosome aneuploidy in fragile X carriers (pages 537–544)

      Karen Brøndum Nielsen, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230146

    4. A possible fragile-site at Yq12: Case report and possible relevance to de novo structural rearrangements of the Y-chromosome (pages 545–555)

      Jeanette J. A. Holden, Patricia Ridgway, Anne Smith, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230147

    5. The fragile X in cattle (pages 557–562)

      Dr. Irene A. Uchida, Viola C. P. Freeman, Parvathi K. Basrur and John M. Opitz

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230148

  17. Letter to the Editor

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Analysis of sister chromatid exchanges in fra(X) individuals (pages 563–566)

      Paula Gregory, Nancy Wang, Patricia N. Howard-Peebles, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230149

  18. III. Epidemiology and Genetics: A. Prevalence

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Studies of the fragile (X) syndrome in populations of mentally retarded individuals in Hawaii (pages 567–572)

      Patricia A. Jacobs, Martha Mayer, Michael A. Abruzzo, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230150

    2. Population incidence and segregation ratios in the Martin-Bell syndrome (pages 573–580)

      Dr. Tessa P. Webb, Sarah E. Bundey, Ann I. Thake, June Todd, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230151

    3. Prevalence of the fragile-X syndrome in mentally retarded boys in a Swedish county (pages 581–587)

      Karl-Henrik Gustavson, Hans Blomquist K:son, Gösta Holmgren, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230152

    4. Fragile X mental retardation: Prevalence in a group of institutionalized patients in Italy and description of a novel EEG pattern (pages 589–595)

      S. Sanfilippo, R. M. Ragusa, S. Musumeci, G. Neri, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230153

    5. The Martin-Bell syndrome in South Africa (pages 597–610)

      Philip A. Venter, Johann Op't Hof, Dennis J. Coetzee, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230154

  19. III. Epidemiology and Genetics: B. Genetics And Segregation

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. The fragile(X) syndrome: The mutation problem (pages 611–617)

      Patricia A. Jacobs, Stephanie Sherman, Gillian Turner, Tessa Webb, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230155

    2. Normal male carriers in the fra(X) form of X-linked mental retardation (Martin—Bell syndrome) (pages 619–631)

      Dr. U. Froster-Iskenius, B. C. McGillivray, F. J. Dill, J. G. Hall, D. S. Herbst, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230156

  20. IV. DNA and Hypotheses: A. DNA and Linkage

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. DNA studies of X-linked mental retardation associated with a fragile site at Xq27 (pages 633–642)

      Kay E. Davies, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230157

    2. DNA linkage studies in the fragile X syndrome suggest genetic heterogeneity (pages 643–664)

      W. Ted Brown, Anne C. Gross, Colin B. Chan, Edmund C. Jenkins, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230158

    3. An assessment of the use of flanking DNA markers for fra(X) syndrome carrier detection and prenatal diagnosis (pages 665–683)

      Cynthia J. Forster-Gibson, Lois M. Mulligan, Nancy E. Simpson, Bradley N. White, Dr. Jeanette J. A. Holden, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230159

  21. IV. DNA and Hypotheses: B. Hypothesis

    1. Top of page
    2. Masthead
    3. Editorial Comment
    4. Conference Report
    5. Articles
    6. Invited Editorial Comment
    7. Articles
    8. I. Clinical Aspects: A. Phenotype
    9. Addendum
    10. I. Clinical Aspects: A. Phenotype
    11. Brief Clinical Report
    12. I. Clinical Aspects: A. Phenotype
    13. I. Clinical Aspects: B. Folic Acid Treatment
    14. I. Clinical Aspects: C. Prenatal Diagnosis
    15. II. Cytogenetic Aspects: A. Fragile Site Expression
    16. Letter to the Editor
    17. II. Cytogenetic Aspects: B. Cytogenetics
    18. Letter to the Editor
    19. III. Epidemiology and Genetics: A. Prevalence
    20. III. Epidemiology and Genetics: B. Genetics And Segregation
    21. IV. DNA and Hypotheses: A. DNA and Linkage
    22. IV. DNA and Hypotheses: B. Hypothesis
    1. Inheritance of fragile X syndrome: An hypothesis (pages 701–713)

      J. M. Friedman, Patricia N. Howard-Peebles, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230161

    2. Recombination and amplification of pyrimidine-rich sequences may be responsible for initiation and progression of the Xq27 fragile site: An hypothesis (pages 715–721)

      Robert L. Nussbaum, Susan D. Airhart, David H. Ledbetter, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230162

    3. Maternal effect on intelligence in fragile X males and females (pages 723–737)

      Daniel L. van Dyke, Lester Weiss, John M. Opitz and James F. Reynolds

      Version of Record online: 3 JUN 2005 | DOI: 10.1002/ajmg.1320230163

SEARCH

SEARCH BY CITATION